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Background: Some of cannabinoids, which are chemical compounds contained in marijuana, are
immunosuppressive. One of the receptors, CB receptor 1 (CB1), is expressed predominantly by the cells in the
central nervous system, whereas CB receptor 2 (CB2) is expressed primarily by immune cells. Theoretically, selective
CB2 agonists should be devoid of psychoactive effects. In this study, we investigated therapeutic effects of a
selective CB2 agonist on arthritis.
Methods: The expression of CB2 was analyzed with immunohistochemistry and Western blotting. Interleukin (IL)-6,
matrix metalloproteinase-3 (MMP-3), and chemokine (C-C motif) ligand 2 (CCL2) were quantified with enzyme-linked
immunosorbent assays (ELISA). Osteoclastogenesis was assessed with tartrate-resistant acid phosphatase staining and
the resorption of coated-calcium phosphate. Effect of JWH133, a selective CB2 agonist, on murine collagen type II
(CII)-induced arthritis (CIA) was evaluated with arthritis score, and histological and radiographic changes. IFN-γ and
IL-17 production by CII-stimulated splenocytes and serum anti-CII Ab were analyzed by ELISA.
Results: Immunohistochemistry showed that CB2 was expressed more in the synovial tissues from the rheumatoid
joints than in those from the osteoarthritis joints. CB2 expression on RA FLS was confirmed with Western blot analysis.
JWH133 inhibited IL-6, MMP-3, and CCL2 production from tumor necrosis factor-α-stimulated fibroblast-like
synoviocytes (FLS) derived from the rheumatoid joints, and osteoclastogenesis of peripheral blood monocytes.
Administration of JWH133 to CIA mice reduced the arthritis score, inflammatory cell infiltration, bone destruction, and
anti-CII IgG1 production.
Conclusion: The present study suggests that a selective CB2 agonist could be a new therapy for RA that inhibits
production of inflammatory mediators from FLS, and osteoclastogenesis.
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MonocyteBackground
Rheumatoid arthritis (RA) is a systemic autoimmune
disease of unknown etiology. It is associated with chronic
inflammation, bone destruction in multiple joints, and vari-
ous extra-articular manifestations. Unless treated properly,
it is generally progressive with functional decline, significant* Correspondence: nanki@med.teikyo-u.ac.jp
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[1]. Recently, biological agents, represented by anti-tumor
necrosis factor (TNF) monoclonal antibodies (mAb), have
been used widely to improve arthritis and to inhibit bone
destruction. However, there remain patients who do not re-
spond satisfactorily. While pain control is a significant issue
for the patients, disease-modifying antirheumatic drugs
(DMARDs) do not have immediate effects for pain relief.
The patients have to depend on corticosteroids or non-
steroidal anti-inflammatory drugs (NSAIDs).
Cannabinoids are pharmacologically active compo-
nents of Cannabis sativa. The endogenous ligands for
cannabinoid receptors represented by anandamide andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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system regulates various physiological processes such as
appetite control, pain perception and immune responses.
Cannabinoids transmit signals through cannabinoid (CB)
receptors, CB receptor 1 (CB1) and CB receptor 2 (CB2)
[2,3]. CB1 is expressed predominantly by the cells in the cen-
tral nervous system (CNS), whereas CB2 is expressed primar-
ily by immune cells [2,3] and by peripheral nerve terminals
[4]. Recently, G-coupled receptor 55 (GPR55) was proved to
be a receptor of many endocannabinoids [5,6]. It is expressed
ubiquitously in many organ systems, including CNS [7].
Furthermore, endocannabinoids act as agonists of transient
receptor potential vanilloid type-1 and type-4 (TRPV-1, -4)
[8,9], and nuclear peroxisome proliferator-activated receptors
(PPARs) [10]. Because of the potential effects on a wide
variety of the receptors in the various organs, cannabinoids
have not been accepted as therapeutic agents. Especially, the
major concerns are their psychoactive effects such as cata-
lepsy and hypolocomotion. In this regards, selective CB2 ago-
nists should be devoid of psychoactive activities.
Immune cells sensitive to cannabinoids are macrophages,
natural killer cells, T cells, and B cells [11]. Some cannabi-
noids were applied to treat collagen-induced arthritis (CIA),
which is a murine model of RA. HU320, a synthetic canna-
binoid ameliorated established CIA [12]. Since HU320 has
no affinity for CB1 or CB2, its therapeutic effect on CIA
may derive from actions on other receptors. Blockade of
fatty acid amide hydrolase (FAAH), which is the primary
degradative enzyme of anandamide, and acts as an agonist
for CB1, CB2 and other receptors, reduced the severity of
CIA [13]. However, therapeutic effect of selective CB2 ago-
nists on animal models of RA has not been investigated.
It was reported that local administration of JWH133,
which is a selective CB2 agonist with 200-fold selectivity for
CB2 over CB1 (Ki values are 3.4 and 677 nM respectively)
[14], inhibited pain reaction of mice with carrageenan-
injected paws [15]. NSAIDs and corticosteroids have several
toxicities especially in long-term treatment or at high doses.
In many cases, opioid analgesics would be better choice for
avoiding the toxicities. Add-on therapy for RA patients with
tramadol, which is a weak opioid analgesic and acetamino-
phen combination tablet, significantly improved joint pain
without severe adverse effects [16]. Thus, selective CB2 ago-
nists would be expected not only to relief pain, but also to
suppress arthritis.
In the present study, we investigated the expression of
CB2 in the RA synovial tissues, in vitro effects of JWH133
on RA fibroblast-like synoviocytes (FLS) and human mono-
cytes, and its in vivo therapeutic effects on CIA.
Methods
Specimens
Synovial tissue samples were obtained from seven RA
patients, who fulfilled the ACR classification criteria [17]and three osteoarthritis (OA) patients undergoing total
knee joint replacement. The RA patients were 62 (38-75)
years old [median (range)], with a disease duration of 9
(3-15) years and C-reactive protein level of 4.6 (0.3-81) mg/l.
Informed consent was obtained from all the patients.
All experimental protocols were approved by the Ethics
Committee of Tokyo Medical and Dental University.
Immunohistochemistry
Immunohistochemical analysis was conducted on formalin-
fixed paraffin-embedded sections of synovial tissues.
The sections were incubated overnight at 4°C with
2 μg/ml rabbit anti-CB2 polyclonal antibody (pAb)
(abcam, Cambridge MA) or normal rabbit IgG as a control.
Subsequently, the samples were incubated with 2 μg/ml bi-
otinylated goat anti-rabbit IgG (Santa Cruz Biotechnology,
Dallas, TX) for 30 min at room temperature, and then incu-
bated for 30 min with streptavidin–horseradish peroxidase
(Dako, Glostrup, Denmark). Diaminobenzidine (Dako) was
used for visualization. The sections were counterstained
with hematoxylin. The CB2 staining of three RA and
three OA samples was semi-quantitatively evaluated by
randomly selected three fields with scored as follows:
0 = none, 1 = focal, and 2 = diffuse. The maximum score
was six for each sample.
For immunofluorescence double-staining with CD68,
CD4, CD8, CD21 or vimentin, and CB2, the sections were
incubated overnight at 4°C with 2 μg/ml rabbit anti-CB2
pAb or normal rabbit IgG together with 1 μg/ml mouse
anti-CD68 mAb (KP1; Dako), 1 μg/ml mouse anti-CD4
mAb (RPA-T4; eBioscience, San Diego, CA), 1 μg/ml mouse
anti-CD8 mAb (HIT8a; BD Bioscience, San Diego, CA),
1 μg/ml mouse anti-CD21 mAb (1 F8; Dako) or 1 μg/ml
mouse anti-vimentin mAb (V9; Dako). Subsequently, the
samples were incubated with 2 μg/ml Alexa Fluor 488-
conjugated goat anti-mouse IgG1 (Invitrogen, Grand Island,
NY) and Alexa Fluor 568-conjugated goat anti-rabbit IgG1
(Invitrogen) for 30 min at room temperature. A nuclear
stain was performed with 4’, 6-diamidino-2-phenylindole.
Protein detection in cultured FLS
FLS from the RA synovial tissues was cultured as was
reported previously [18]. RA FLS was lysed with radio-
immunoprecipitation assay buffer (Millipore, Billerica,
MA, USA) for 30 min at 4°C. A total of 20 μg of protein
were boiled in the presence of sodium dodecyl sulfate (SDS)
sample buffer and separated on a 10% SDS-polyacrylamide
gel (ATTO, Tokyo, Japan). Proteins were then electro-
transferred onto a polyvinylidene fluoride microporous
membrane (Millipore) in a semidry system. The mem-
brane was blocked with Block Ace (Snow Brand Milk
Products, Tokyo, Japan) for 1 h at room temperature,
and then the immunoblots were incubated overnight
with 1 μg/ml rabbit anti-CB2 pAb in Can Get Signal
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Japan) at 4°C. After washing, the immunoblots were incu-
bated with 2 μg/ml biotinylated goat anti-rabbit IgG for
30 min at room temperature, and then incubated for 30 min
with streptavidin–horseradish peroxidase. ECL Prime
detection reagent and the ImageQuant LAS 4000 Mini
Biomolecular Imager (both from GE Healthcare) were
used to detect the bands.
RA FLS (1 × 105 cells/ml) was cultured in Dulbecco's
Modified Eagle Medium (Sigma-Aldrich) + 10% fetal bovine
serum (FBS) (Sigma-Aldrich) and stimulated with 5 ng/ml
recombinant TNF-α (R&D Systems, Minneapolis, MN)
for 24 h in the presence or absence of JWH133 (Tocris
bioscience, Ellisville, MO) [14]. The concentrations of
Interleukin (IL)-6, metalloproteinase-3 (MMP-3) and
chemokine (C-C motif) ligand 2 (CCL2) in the culture su-
pernatants were measured using enzyme-linked immuno-
sorbent assay (ELISA) kits (DuoSet; R&D Systems).
Analysis of osteoclastogenesis
Peripheral blood mononuclear cells from healthy donors
were collected using Ficoll-Conray (Imuuno-Biological
Laboratories, Gunma, Japan) gradient centrifugation.
Positive selection of CD14+ monocytes was performed
using CD14 MicroBeads (Miltenyi Biotec, Auburn, CA).
The purified peripheral blood CD14+ monocytes (1 × 106
cells/well) were incubated in 96-well plates in α-Minimum
Essential Medium (Sigma-Aldrich) with 10% FBS, and incu-
bated with 25 ng/ml macrophage colony-stimulated factor
(M-CSF) (R&D systems) + 40 ng/ml receptor activator of
nuclear factor kappa-B ligand (RANKL) (Peprotech, Rocky
Hill, NJ). These cells incubated in the presence or absence
of JWH133. The medium was replaced with fresh medium
3 days later, and after incubation for 7 days the cells were
stained for tartrate-resistant acid phosphatase (TRAP) ex-
pression using a commercial kit (Hokudo, Sapporo, Japan).
The number of TRAP-positive multinucleated cells (MNC:
more than 3 nuclear) in a randomly selected field examined
at ×40 magnification was counted under light microscopy.
The CD14+ monocytes were seeded onto plates coated
with calcium phosphate thin films (Osteo Assay Plate,
Corning, NY, USA) and were incubated with 25 ng/ml
M-CSF + 40 ng/ml RANKL for 7 days in the presence or
absence of JWH133. The cells were then lysed in bleach
solution (6% NaOCl, 5.2% NaCl). The resorption lacunae
were examined under light microscopy. The viability of
the cells treated with JWH133 (up to 50 μM) was more
than 95% relative to the vehicle-treated cells.
Induction of collagen-induced arthritis (CIA)
Male 8-week-old DBA/1 J mice were purchased from
Oriental Yeast (Tokyo, Japan) and were kept in the
temperature of 23.5 ± 2 degrees Celsius with 40-50%
humidity. Bovine collagen type II (CII; Collagen ResearchCenter, Tokyo, Japan) was dissolved in 0.05 M acetic acid
at 4 mg/ml and emulsified in equal volume of complete
Freund’s adjuvant (CFA; Difco Laboratories, Detroit, MI).
Mice were immunized with 100 μl of the emulsion injected
intracutaneously at the base of the tail (day 1). After 21 days
(day 22), the same amount of bovine CII emulsified in CFA
was injected intracutaneously at the base of the tail as a
booster immunization [19].
Treatment of collagen-induced arthritis (CIA) mice
with JWH133
Twelve mice with CIA per group were twice daily
injected intraperitoneally with JWH133, 1 mg/kg/day or
4 mg/kg/day in total volume of 200 μl/day of 20% dimethyl
sulphoxide or vehicle alone from day 15 to day 35. To
determine the therapeutic effects of JWH133, we also
treated mice with 4 mg/kg JWH133 from day 28, after
the development of arthritis, to day 35 and observed
the mice for signs of arthritis. Disease severity for each
limb was recorded as follows: 0 = normal, 1 = erythema
and swelling of one digit, 2 = erythema and swelling of two
digits or erythema and swelling of ankle joint, 3 = erythema
and swelling of more than three digits or swelling of
two digits and ankle joint, and 4 = erythema and severe
swelling of the ankle, foot, and digits with deformity.
The clinical arthritis score was defined as the sum of
the scores for all 4 paws of each mouse. Thickness of
each paw was measured using a pair of digital slide
calipers. On day 36, the ankle joints were harvested
and examined radiographically and histologically. The
bilateral second-to-fourth metatarsophalangeal (MTP)
joints were assessed radiographically as follows: 0 = not
obvious, 1 = marginal osteoporosis, and 2 = erosion.
This system yields a possible score between 0 and 4 per
animal. The hind paw of each mouse was dissected
and examined histologically after hematoxylin and
eosin staining. The severity of arthritis was evaluated
according to synovial inflammation, as follows: 0 = no
inflammation, 1 = focal inflammatory infiltration, and
2 = severe and diffuse inflammatory infiltration. The
experimental protocol was approved by the Institutional
Animal Care and Use Committee of Tokyo Medical and
Dental University.
The harvested splenocytes (1 × 106 cells) on day 36 were
cultured in 48-well plates in Roswell Park Memorial
Institute 1640 medium (Sigma-Aldrich) with 10% FBS
supplemented with 50 μg/ml denatured (100°C, 10 min)
CΙΙ. After 72 h, the concentrations of interferon (IFN)-γ
and IL-17 in the culture supernatant were measured using
ELISA kits (DuoSet; R&D Systems).
Serum samples were obtained on day 36 for measure-
ment of IgG1 anti-CII antibody by ELISA (normal, n = 4;
vehicle, n = 12; 4 mg/kg JWH133, n = 12) as described
previously [19].
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All data are expressed as the mean ± standard error of the
mean (SEM). Immunohistological score was analyzed by
student’s t-test. Concentration of inflammatory mediators
and osteoclastogenesis were analyzed by Kruskal-Wallis
test and Dunnett’s test. Overtime analysis of arthritis score
and paw thickness was performed by 2 way-ANOVA,
and point-by-point analysis was followed by student’s
t-test. Histological and radiographic score, and con-
centration of IgG1 were analyzed by Kruskal-Wallis
test and student’s t-test.
Results
CB2 expression in the RA synovial tissues and cells
The RA and OA synovial tissues were examined for CB2
expression with immunohistochemical staining. We found
positive staining in the lining, and sub-lining layer
(Figure 1A), and follicle-like aggregates (Figure 1B). In
contrast, minimal staining was observed in the OA
synovial tissues (Figure 1C). No signal was observed on
specimens stained with an isotype-matched IgG con-
trol of irrelevant specificity (Figure 1D). The CB2 stain-
ing of 3 RA and 3 OA samples was evaluated with
immunohistological score. The scores of CB2 staining
of RA samples was significantly higher than that of OA
samples (Figure 1E).
In consistence with the fact that macrophages and
lymphocytes express CB2 [20,21], immunofluorescence
double staining of the RA synovial tissues revealed CB2
expression on the synovial CD68+ macrophages, CD4+
T cells, CD8+ T cells, CD21+ B cells and vimentin+
fibroblast-like appearance cells (Figure 1F).
Inhibition of inflammatory mediator production from RA
FLS with a selective CB2 agonist
FLS produce various inflammatory mediators that play
important roles in development of RA. CB2 expression
on in vitro cultured RA FLS was confirmed with Western
blot analysis (Figure 2A), which agreed with previous
observation [22]. We evaluated effects of JWH133, a
selective CB2 agonist, on the production of IL-6, MMP-3,
and CCL2 from FLS stimulated with TNF-α. TNF-α treat-
ment enhanced production of these mediators from RA
FLS, which was suppressed by JWH133 dose-dependently
(Figure 2B-D). Treatment with JWH133 did not inhibit the
proliferation of FLS evaluated with the cell counting kit
(Dojindo, Kumamoto, Japan) using WST-8, 2-(2-methoxy-
4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium (data not shown).
Inhibition of osteoclastogenesis of peripheral blood
monocytes with a selective CB2 agonist
In the following experiments, we used human peripheral
blood CD14+ monocytes, which have been shown toexpress CB2 [23], since it is hard to prepare a large number
of synovial macrophages. Incubation of peripheral blood
CD14+ monocytes with M-CSF and RANKL promoted
development of TRAP-positive multinucleated cells. Co-
incubation with JWH133 suppressed osteoclast formation
dose-dependently (Figure 3A and B). M-CSF and RANKL
treatment induced resorption of coated calcium. This
was inhibited by the co-incubation with JWH133 dose-
dependently (Figure 3C and D). These data showed
that JWH133 inhibited the formation and function of
human osteoclasts.
Treatment of murine CIA with JWH133
The inhibitory effects of JWH133 on RA FLS and human
osteoclasts prompted us to examine the compound for the
inhibitory effects on murine CIA, an animal model of RA.
Intraperitoneal administration of JWH133 (1 mg/kg/day or
4 mg/kg/day) or vehicle twice daily was initiated two weeks
after the first immunization and continued for 21 days.
Treatment with JWH133 (4 mg/kg/day) ameliorated clin-
ical severity of the arthritis (Figure 4A and B). However, the
incidence of arthritis was 100% in all groups. On day 36,
the ankle joints were harvested and examined histologically
and radiographically. Cell infiltration in the synovial tissues
and radiographical bone destruction were observed in
vehicle-treated CIA mice, and reduced significantly in
the JWH133-treated mice (Figure 4C,D,E and F).
Splenocytes from the mice at day 36 were stimulated
with CII and the production of IFN-γ and IL-17 was
measured. IFN-γ and IL-17 production was upregulated
by the CII stimulation. The treatment with JWH133 did
not alter the cytokine production (Figure 4G and H). To
determine the effect of JWH133 on anti-CII antibody
production, we measured serum anti-CII IgG1 antibody
titer by ELISA on day 36. While anti-CII IgG1 antibody
was not detected in normal mice, it was detected in CIA
mice. The treatment with JWH133 significantly lowered
anti-CII IgG1 antibody level (Figure 4I). Although IgG2a
and IgG2b anti-CII antibodies were also detected in CIA
mice, treatment with JWH133 did not significantly alter
the levels of antibodies (data not shown).
To examine the therapeutic effects of JWH133 after
the onset of the arthritis, we treated the CIA mice with
4 mg/kg JWH133 from day 28 to day 35, and observed
inhibition of the arthritis (Figure 5A and B).
Discussion
The present studies demonstrated that the selective CB2
agonist, JWH133 inhibited production of IL-6, MMP-3
and CCL2 from FLS and M-CSF and RANKL-induced
osteoclastogenesis of monocytes/macrophages. Admin-
istration of JWH133 ameliorated arthritis severity and
bone destruction, and decreased anti-CII IgG1 anti-
body in a murine model of RA. This effectiveness could
Figure 1 CB2 expression in the RA synovial tissues. Synovial tissue samples from patients with RA (A, B, D) or with OA (C) were stained with
anti-CB2 pAb (A B, and C), or normal rabbit IgG (D). All sections were counterstained with hematoxylin. Bar, 400 μm. The representative figures of
three RA and three OA synovial tissues are depicted. The severity of the CB2 staining of samples was shown (E). Double immunofluorescence
staining of the RA synovial tissues with CB2 and CD68, CD4, CD8, CD21 or vimentin, and DAPI are shown (F). Arrows indicate double-positive cells
in the merged image. Bar, 40 μm. *p < 0.05.
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Figure 2 Inhibition of IL-6, MMP-3, and CCL2 production from FLS by the selective CB2 agonist JWH133. CB2 expression on in vitro
cultured FLS from three RA patients was detected with Western blotting analysis (A). Bars indicate 50 and 37 kDa. Predicted molecular weight of
CB2 is 45 kDa. RA FLS were treated with various concentrations of JWH133, from 30 minutes before the stimulation with TNF-α for 24 h.
Concentrations of IL-6 (B), MMP-3 (C), and CCL2 (D) in the cultured supernatants were measured with ELISA. Data is presented as means ± SEM
of one of three independent experiments analyzed in quadruplicate. *p < 0.05, **p < 0.01.
Figure 3 Effects of the selective CB2 agonist JWH133 on peripheral blood monocytes. Peripheral blood monocytes were treated with
various concentrations of JWH133, from 30 minutes before the stimulation with M-CSF and RANKL. Cells were stained with TRAP (A). TRAP-positive
multinucleated cells in a randomly selected field examined at ×40 magnification were counted (B). Representative data (mean ± SEM) from one of
three independent experiments analyzed in triplicate are shown. The osteoclasts were incubated on calcium phosphate-coated plates (C). The area of
resorption lacunae was examined under light microscopy (D). Representative data (mean ± SEM) from one of three independent experiments analyzed
in triplicate are shown. Bar, 400 μm. *p < 0.05, **p < 0.01.
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Figure 4 (See legend on next page.)
Fukuda et al. BMC Musculoskeletal Disorders 2014, 15:275 Page 7 of 10
http://www.biomedcentral.com/1471-2474/15/275
(See figure on previous page.)
Figure 4 Effects of the selective CB2 agonist, JWH133 on CIA mice. JWH133 (1 mg/kg/day or 4 mg/kg/day) or vehicle (n = 12 each) was
injected intraperitoneally twice daily from day 15 to day 35. The arthritis severity was recorded as the arthritis score (A) and paw thickness (B).
Overtime analysis of arthritis score and paw thickness by 2-way ANOVA revealed significant difference between vehicle group and 4 mg/kg/day
grope (p < 0.01). Representative hematoxylin and eosin staining of ankle joints from normal mice and from mice with CIA after the treatment with
vehicle or JWH133 (4 mg/kg/day) are shown (C). Bar, 200 μm. Inflammatory cell infiltration in the ankle joints was evaluated with the histological
score (D). Representative radiographs of the ankle joints of normal mice and CIA mice treated with vehicle or JWH133 (4 mg/kg/day) (E). Arrows
indicate bone erosion. Bone erosion in the bilateral MTP joints was evaluated with the bone destruction score (F). Splenocytes from normal mice
and CIA mice treated with vehicle or JWH133 (4 mg/kg/day) were cultured with CII for 72 h. Concentrations of IFN-γ (G) and IL-17 (H) in the
cultured supernatant were measured by ELISA. N: normal, V: vehicle, J: JWH133, NS: not significant. Serum samples were obtained at day 36 from
normal mice and CIA mice treated with vehicle or JWH133 (4 mg/kg/day), and anti-CII IgG1 antibody level was measured by ELISA (I). Values are
the mean ± SEM. *p < 0.05 versus vehicle.
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diator secretion from FLS and osteoclastogenesis and
autoantibody production. Thus, selective CB2 agonists
could be a therapeutic agent for RA.
While medical use of cannabinoids such as sedation
and analgesia was recorded in 19th century [24], narcotic
addiction was always concerned. Recent identification of
cannabinoid receptors revealed two distinctive receptors,
CB1 and CB2, and putative third receptor, GPR55. Some
cannabinoids also act as agonists of TRPV-1, -4 and PPARs.
It is expected that selective CB2 agonists act as therapeutic
agents that modulate immune functions without any psy-
choactive effects. JWH133 was applied to our study since it
has high selectivity for CB2 against CB1 and has no affinity
for GPR55, TRPV-1, -4 or PPARs.
In RA patients, FLS expresses hyperplastic, inflammatory,
cartilage- and bone-destructive phenotypes. Cytokines,
chemokines and MMPs are secreted by FLS. It was re-
ported that MMP-3 production from FLS stimulated
with TNF-α or IL-1β was suppressed by ajulemic acid,
a synthetic cannabinoid [22]. However, the receptors of
this compound have not been identified. In this study,
we showed that the selective CB2 agonist, JWH133 sig-
nificantly reduced the production of IL-6, MMP-3, and
CCL2 from FLS stimulated with TNF-α.Figure 5 Therapeutic effect of JWH133 on CIA. CIA mice were treated w
(n=12 each) twice daily from day 28 to day 35, after the onset of the disea
thickness (B). Overtime analysis of arthritis score and paw thickness by 2-w
4 mg/kg/day grope (p < 0.01). Values are the mean ± SEM. *p < 0.05, **P < 0IL-6 has a wide range of functions on immune cells,
and plays an important role in RA [25]. Blockade of IL-6
signaling by anti-IL-6 or -IL-6 receptor mAbs is effective
treatment [26,27]. Among various chemokines, only CCL2
gene expression is reportedly higher in RA FLS than in OA
FLS [28]. Monocyte migration induced by RA stromal cell
line supernatants was blocked with anti-CCL2 mAbs [29].
MMP-3 was highly expressed in the RA pannus tissues
[30]. In the cytoplasm, CB2 stimulation leads to inhibition
of adenylyl cyclase and subsequent decrease of the intracel-
lular cAMP level. It results in decreased activity of protein
kinase A and transcription factors such as NF-κB and
NFAT [31,32]. Thus, the treatment of JWH133 could sup-
press other inflammatory mediators than IL-6, CCL2 and
MMP-3, which are involved in pathology of the arthritis.
JWH133 may affect other types of cells involved in the
arthritis. RANTES/CCL5-induced chemotaxis of macro-
phages was inhibited with delta-9-tetrahydrocannabinol,
the major component in marijuana, acting through
CB2 [33]. Anandamide, one of endocannabinoids, sup-
pressed IL-17 production from Th17 cells primarily
via CB2 [34]. JWH015, another selective CB2 agonist,
inhibited CXCL12-induced chemotaxis of T cells [35].
We found that CB2 was expressed broadly in the RA
synovial cells including macrophages, T cells, and B cells.ith intraperitoneal injection of JWH133 (4 mg/kg/day) or vehicle
se. The arthritis severity was recorded as the arthritis score (A) and paw
ay ANOVA revealed significant difference between vehicle group and
.01 versus vehicle.
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of the arthritis.
It was reported that CB2-deficient mice develop osteo-
porosis with age [36]. HU308, another selective CB2 agon-
ist, inhibited osteoclast formation of RANKL-stimulated
RAW264.7 cells as well as bone marrow cells from normal
mice but not from CB2-deficient mice [36]. In agreement
with this observation, we demonstrated that JWH133
inhibited osteoclastogenesis of human peripheral blood
monocytes and bone destruction of CIA mice. Since bone
destruction is often a serious issue in RA patients as well as
chronic pain and can result in functional decline, inhibitory
effect of selective CB2 agonists for osteoclastogenesis could
be another feature in RA treatment.
In this study, we observed amelioration of CIA with
JWH133. Since T helper cell differentiation influences the
development of CIA [37,38], we measured the production
of IFN-γ and IL-17 by CII-stimulated splenocytes from the
CIA mice. No significant difference among the groups was
revealed in our study. It is suggested that the treatment
with JWH133 did not affect Th1 and Th17 differentiation,
which may not be attributable to the amelioration of CIA.
On the other hand, the treatment with JWH133 decreased
the level of serum anti-CII IgG1 antibody. In the previous
study, CB2 mRNA was detected in peripheral B cells [20].
We determined CB2 expression on B cells in RA synovial
tissue. Although the effect of CB2 for immunoglobulin
production has not been reported, the administration of
JWH133 directly or indirectly may affect B cells to sup-
press anti-CII IgG1 antibody production of CIA mice and
contribute to the amelioration of the arthritis.
This is the first report of therapeutic effect of a select-
ive CB2 agonist on CIA. Although the effect was mild,
optimization of dosage and/or treatment protocol might
enhance the effect. Perhaps, more potent selective CB2
agonists might solve this problem.
Conclusions
We demonstrated that JWH133, the selective CB2 agonist,
provides clinical effectiveness against CIA mice probably
through the immunosuppressive effects for FLS and mono-
cytes and inhibition of anti-CII Ab production. Addition to
the analgesic effect as previously reported, selective CB2
agonists could be a new therapy for RA.
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